Psyched Services Competitors

We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We further our mission by: ● Developing psychedelics and marijuana into prescription medicines ● Training therapists and working to establish a network of treatment centers ● Supporting scientific research into spirituality, creativity, and neuroscience ● Educating the public honestly about the risks and benefits of psychedelics and marijuana